Abstract

Epoetin alfa appears to be effective and well tolerated in preventing hemoglobin decline in patients undergoing aggressive cyclic platinum-based chemotherapy for advanced ovarian carcinoma.

Keywords

MedicineEpoetin alfaErythropoietinChemotherapyAnemiaCarboplatinInternal medicineHemoglobinOvarian carcinomaOvarian cancerCisplatinOncologyNephrotoxicityUrologyGastroenterologyCancerToxicity

Affiliated Institutions

Related Publications

Research Agenda for Frailty in Older Adults: Toward a Better Understanding of Physiology and Etiology: Summary from the American Geriatrics Society/National Institute on Aging Research Conference on Frailty in Older Adults

Jeremy Walston , Marianne Nygaard , Luigi Ferrucci +6 more

Evolving definitions of frailty, and improved understanding of molecular and physiological declines in multiple systems that may increase vulnerability in frail, older adults ha...

2006 Journal of the American Geriatrics So... 1589 citations

Publication Info

Year
2006
Type
article
Volume
1
Issue
4
Pages
261-6
Citations
40
Access
Closed

External Links

Citation Metrics

40
OpenAlex

Cite This

Richard Welch, R.D. James, P. M. Wilkinson et al. (2006). Recombinant human erythropoietin and platinum-based chemotherapy in advanced ovarian cancer.. PubMed , 1 (4) , 261-6.